

ERYTHROPOIESIS STIMULATING AGENTS (ESAs)

Prior Authorization Form

ARANESP, EPOGEN, & PROCRIT

- Standard Request (72 hours) If you or your prescriber believe that waiting 72 hours for a standard decision could seriously harm your life, health, or ability to regain maximum function, you can request an expedited decision. For expedited requests you will receive a decision within 24 hours. You cannot request an expedited coverage determination if you are requesting reimbursement for a drug you already received.
- Expedited Request (24 hours)

Demographics

Patient Information

Prescriber Information

Patient Name:		Prescriber Name:	
DOB:	Age:	NPI#:	Specialty:
Health Plan ID#:	Phone:	Fax:	
Pharmacy Name:	Pharmacy Phone:	Office Contact:	Direct Phone # or Ext:

Medication Information

Drug Requested:	Strength:	Directions:
Quantity Dispensed:	Day Supply:	<input type="checkbox"/> Generic <input type="checkbox"/> Brand Necessary
<i>Generic equivalent drugs will be substituted for Brand name drugs unless you specifically indicate otherwise.</i>		
<input type="checkbox"/> New medication <input type="checkbox"/> Continuation of therapy	Start Date:	If this is continuation of therapy, please provide CHART DOCUMENTATION indicating the member showed improvement while on therapy.

Billing Information

<input type="checkbox"/> Billed by PHARMACY dispensed to the member or provider for administration.	<input type="checkbox"/> Billed under MEDICAL benefit by provider.	Place of Administration:
J CODE: _____	ICD-10 Code: _____	<input type="checkbox"/> Physician's Office <input type="checkbox"/> Hospital/Clinic <input type="checkbox"/> Patient Home

Clinical Information

Diagnosis:	Date Diagnosed:
Hgb level (g/dL): _____	Date of test: _____
<input type="checkbox"/> Anemia due to chronic kidney disease	Is member on renal dialysis? <input type="checkbox"/> Yes <input type="checkbox"/> No
<input type="checkbox"/> Non-myeloid malignancy on chemotherapy	Does member have at least 2 more months of planned chemotherapy? <input type="checkbox"/> Yes <input type="checkbox"/> No
<input type="checkbox"/> Reduction of risk for allogenic blood transfusions (EpoGen and Procrit)	Is patient at high risk for perioperative transfusion? <input type="checkbox"/> Yes <input type="checkbox"/> No
	Is patient scheduled to undergo elective, non-cardiac or nonvascular surgery? <input type="checkbox"/> Yes <input type="checkbox"/> No
<input type="checkbox"/> Ribavirin-induced anemia (EpoGen and Procrit)	Was the dose of ribavirin reduced to see if symptoms of anemia resolved? <input type="checkbox"/> Yes <input type="checkbox"/> No

<input type="checkbox"/> Anemia due to other cause	If Yes, please submit chart documentation indicating rationale for therapy and supportive lab values.
Does member have uncontrolled Hypertension?	<input type="checkbox"/> Yes <input type="checkbox"/> No
Has iron status been evaluated and will continue to be evaluated during therapy?	<input type="checkbox"/> Yes <input type="checkbox"/> No
What is the medication's starting dose?	What is the medication's maintenance dose:
Please provide any additional information which should be considered in the space below:	